Article

Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression

University of Cambridge, Cambridge, England, United Kingdom
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.32). 12/2006; 15(11):2107-14. DOI: 10.1158/1055-9965.EPI-06-0351
Source: PubMed

ABSTRACT Plasminogen activator inhibitor-1 (PAI1) can promote cancer progression, and its protein expression in tumors is an independent indicator of poor prognosis in many forms of cancer. Here, we show that high PAI1 mRNA levels also predict for shorter overall survival in two independent breast cancer data sets, highlighting the importance of its transcriptional regulation. The -675insG (4G/5G) single-nucleotide polymorphism in the PAI1 gene promoter has been shown to influence PAI1 transcription, with the 4G allele eliciting higher reporter gene expression in vitro and higher levels of circulating PAI1 in vivo. Nevertheless, its genotypic distribution in 2,539 British women with invasive breast cancer was virtually identical to that seen in 1,832 matched controls (P = 0.72), and annual mortality rates for 4G4G, 4G5G, and 5G5G cases were 2.6%, 2.8%, and 3.1% per year, respectively (P = 0.10). Thus, there was no association with breast cancer incidence or outcome, and in a separate set of breast cancers, the 4G/5G single-nucleotide polymorphism showed no association with PAI1 mRNA expression (P = 0.85). By contrast, connective tissue growth factor (CTGF), which can regulate PAI1 expression in culture, was associated with PAI1 expression in three independent cohorts (P < 0.0001). In addition, PAI1 gene copy number differences in the tumors were correlated with PAI1 mRNA expression (P = 0.0005) and seemed to affect expression independently of CTGF. Thus, local factors, such as CTGF and genomic amplification, seem to be more important than germ line genetic variation in influencing PAI1 expression and its untoward effects in breast cancer.

Download full-text

Full-text

Available from: Mark D Sternlicht, Aug 18, 2015
0 Followers
 · 
95 Views
  • Source
    • "IL-6 and PAI-1 co-expression in epithelial ovarian cancer C Alberti et al signaling cascade from ligand-stimulated EGFR/MEK/ ERK or EGFR/PI3K/AKT activates the transcriptional activity of NFkB with expression of IL-6 together with PAI-1. A similar signaling pathway has been experimentally demonstrated in glioblastoma cell lines (Paugh et al., 2008), and a positive correlation between PAI-1 and IL-6 gene expression has been observed in a metaanalysis carried out on publicly available data sets of gene expression of breast carcinoma (Sternlicht et al., 2006). Interestingly, very recently ErbB2 expression, another member of the ErbB family, was found to upregulate IL-6 production through the transcriptional activity of NFkB (Hartman et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is expressed in up to 70% of epithelial ovarian cancers (EOCs), where it correlates with poor prognosis. The majority of EOCs are diagnosed at an advanced stage, and at least 50% present malignant ascites. High levels of IL-6 have been found in the ascites of EOC patients and correlate with shorter survival. Herein, we investigated the signaling cascade led by EGFR activation in EOC and assessed whether EGFR activation could induce an EOC microenvironment characterized by pro-inflammatory molecules. In vitro analysis of EOC cell lines revealed that ligand-stimulated EGFR activated NFkB-dependent transcription and induced secretion of IL-6 and plasminogen activator inhibitor (PAI-1). IL-6/PAI-1 expression and secretion were strongly inhibited by the tyrosine kinase inhibitor AG1478 and EGFR silencing. A significant reduction of EGF-stimulated IL-6/PAI-1 secretion was also obtained with the NFkB inhibitor dehydroxymethylepoxyquinomicin. Of 23 primary EOC tumors from advanced-stage patients with malignant ascites at surgery, 12 co-expressed membrane EGFR, IL-6 and PAI-1 by immunohistochemistry; both IL-6 and PAI-1 were present in 83% of the corresponding ascites. Analysis of a publicly available gene-expression data set from 204 EOCs confirmed a significant correlation between IL-6 and PAI-1 expression, and patients with the highest IL-6 and PAI-1 co-expression showed a significantly shorter progression-free survival time (P=0.028). This suggests that EGFR/NFkB/IL-6-PAI-1 may have a significant impact on the therapy of a particular subset of EOC, and that IL-6/PAI-1 co-expression may be a novel prognostic marker.
    Oncogene 12/2011; 31(37):4139-49. DOI:10.1038/onc.2011.572 · 8.56 Impact Factor
  • Source
    • "Recent data suggested that genotyping PAI-1 4G/5G may help in clinical prognosis of BC, but results are contradictory. Although few studies suggested that 4G/4G homozygosity is associated with elevated tissue PAI-1 levels [9] node-positive BC [10], and poor relapse-free (RFS) and overall (OS) survival [11], others suggested an involvement of 5G/5G homozygosity, especially among node negative patients [12], or denied any association between the polymorphism and BC invasiveness [8] [13]. PAI-1 4G/5G polymorphism is a mononucleotide repetitive DNA sequence. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasminogen activator inhibitor (PAI-1) may have an independent prognostic value in breast cancer (BC). PAI-1 4G/5G polymorphism may have significance for antigen expression. Thus, we analyzed the possible associations between PAI-1 4G/5G polymorphism, plasma PAI-1 levels, and clinicopathological features of breast cancer (BC) patients. PAI-1 4G/5G polymorphism (both on germinal and tumor DNA) and plasma PAI-1 levels were investigated in 99 BC patients and 50 unrelated healthy women similar for age and menopausal status. No association was found between allele frequencies and clinicopathological features of BC or plasma antigen levels. Plasma PAI-1 levels were higher in BC compared to controls (p=0.002), particularly in patients with large tumors (p<0.001). 5-year follow-up was achieved in 79 patients: 30% had relapsing disease, 63% with positive compared to 37% with negative PAI-1 levels (p<0.05). 5-year relapse-free survival rate of positive PAI-1 was 46% vs., 77% of negative patients (p=0.02). We may conclude that plasma PAI-1 levels in BC patients could represent a useful prognostic variable for relapse, although PAI-1 polymorphism might not represent a genetic susceptibility factor.
    Thrombosis Research 04/2009; 124(4):403-8. DOI:10.1016/j.thromres.2009.02.014 · 2.43 Impact Factor
  • Source
    Breast Care 11/2008; 3(s2):3-10. DOI:10.1159/000151737 · 0.91 Impact Factor
Show more

Similar Publications